If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now?

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Abbott Laboratories (NYSE:ABT) is a global healthcare company that develops and sells a wide range of health technologies and products.

It is set to report its Q3 2025 earnings on Oct. 15. Wall Street analysts expect the company to post EPS of $1.30, up from $1.21 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $11.41 billion, up from $10.63 billion a year earlier.

Don't Miss:

The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — and you can too at just $2.90/share. Kevin O'Leary Says Real Estate's Been a Smart Bet for 200 Years — This Platform Lets Anyone Tap Into It

If You Bought Abbott Laboratories Stock 10 Years Ago

The company's stock traded at approximately $43.70 per share 10 years ago. If you had invested $10,000, you could have bought roughly 229 shares. Currently, shares trade at $132.29, meaning your investment's value could have grown to $30,261 from stock price appreciation alone. However, Abbott Laboratories also paid dividends during these 10 years.

Abbott Laboratories' dividend yield is currently 1.79%. Over the last 10 years, it has paid about $16.59 in dividends per share, which means you could have made $3,796 from dividends alone.

Summing up $30,261 and $3,796, we end up with the final value of your investment, which is $34,057. This is how much you could have made if you had invested $10,000 in Abbott Laboratories stock 10 years ago. This means a total return of 240.60%. However, this figure is less than the S&P 500 total return for the same period, which was 307.50%.

Trending: An EA Co-Founder Shapes This VC Backed Marketplace—Now You Can Invest in Gaming's Next Big Platform

What Could The Next 10 Years Bring?

Abbott Laboratories has a consensus rating of "Buy" and a price target of $139.60 based on the ratings of 26 analysts. The price target implies more than 5% potential upside from the current stock price.

The company on July 17 announced its Q2 2025 earnings, posting adjusted EPS of $1.26, compared to the consensus estimate of $1.25, and revenues of $11.14 billion, compared to the consensus of $11.07 billion, as reported by Benzinga.

“Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,” said CEO Robert B. Ford. “We see this momentum carrying into 2026.”

Story Continues

Abbott projects its full-year 2025 adjusted diluted EPS to be between $5.10 and $5.20.

See Also: The ECG Hasn't Changed in 100 Years — This AI Upgrade Could Help Detect Heart Disease Years Earlier

Check out this article by Benzinga, which looks into Abbott Laboratories’ recent short interest.

Given the expected upside potential of just 5%, growth-focused investors may not find Abbott Laboratories stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 1.79% and consistent hikes. Abbott Laboratories has raised its dividend consecutively for the last 53 years.

Read Next: Arrived Home's Private Credit Fund’s has historically paid an annualized dividend yield of 8.1%*, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.

Image: Shutterstock

This article If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Benzinga.com

View Comments